All lobbying filings

Leavitt Partners, LLC

Leavitt Partners, LLC filed a Q3 report for Save Rare Treatments Task Force on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for Save Rare Treatments Task Force · Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.

As filed: LEAVITT PARTNERS, LLC for SAVE RARE TREATMENTS TASK FORCE.

All filings by Leavitt Partners, LLC · Everything Save Rare Treatments Task Force has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

ROBERT CLAYTON ALSPACH

Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
JOSH TRENT

Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.